CT47A2: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

Target Name: CT47A2

NCBI ID: G728090

CT47A2

CT47A2: A Potential Drug Target and Biomarker for Cancer and Testis Antigens

CT47A2 is a protein that is expressed in a variety of tissues, including the brain, spleen, heart, and testes. It is also a potential drug target and biomarker for cancer and testis antigens. This protein has been identified as a potential drug target due to its unique structure and its expression in various tissues. In this article, we will discuss the potential drug target and biomarker properties of CT47A2, as well as its potential in cancer and testis antigens.

Potential Drug Target

CT47A2 has been identified as a potential drug target due to its unique structure and its expression in various tissues. The protein has four transmembrane domains and a cytoplasmic tail. It has been shown to interact with various proteins, including the protein kinase B-36.1 (BK-361), which is a key regulator of cell growth and survival.

BK-361 is a non-coding RNA molecule that is expressed in various tissues and is involved in the regulation of cell growth, apoptosis, and angiogenesis. CT47A2 has been shown to interact with BK-361, which suggests that it may be a potential drug target for cancer.

Potential Biomarker

CT47A2 has also been identified as a potential biomarker for cancer and testis antigens. Cancer and testis antigens are proteins that are expressed in various tissues and can be used as targets for diagnostic and therapeutic approaches. CT47A2 has been shown to interact with the testis antigen Muc1, which is a protein that is expressed in the testes and has been associated with various diseases, including testicular cancer.

In addition, CT47A2 has also been shown to interact with the breast cancer antigen Her2, which is a protein that is expressed in various tissues and has been associated with the development and progression of breast cancer.

Potential Applications

The potential drug target and biomarker properties of CT47A2 make it a promising target for cancer and testis antigens. CT47A2 has been shown to interact with various proteins, including BK-361 and Muc1, which suggests that it may be a potential drug target for cancer and testis antigens.

In addition, CT47A2 has also been shown to interact with Her2, which is a protein that is expressed in various tissues and has been associated with the development and progression of breast cancer. This suggests that CT47A2 may also be a potential biomarker for breast cancer.

Conclusion

CT47A2 is a protein that has been identified as a potential drug target and biomarker for cancer and testis antigens. Its unique structure and its expression in various tissues make it a promising target for diagnostic and therapeutic approaches. Further research is needed to fully understand the potential of CT47A2 as a drug target and biomarker for cancer and testis antigens.

Protein Name: Cancer/testis Antigen Family 47 Member A2

The "CT47A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets